Curis' Differentiated Oncology Approach Is Worth More Than The Market Suggests Seeking Alpha Idelalisib generated a complete response rate of 19% and an overall response rate of 97% when combined with rituximab in treatment-naive older patients with chronic lymphocytic leukemia. And Infinity, at the meeting of the American Society for Clinical ... |
